Skip to main content
. 2020 Feb 3;11(8):2060–2067. doi: 10.7150/jca.37991

Figure 3.

Figure 3

(A) Kaplan-Meier plot of acquired T790M mutation risks in patients with EGFR-mutated advanced NSCLC. (B) Kaplan-Meier plot of PFS in T790M-mutated patients treated with osimertinib. PFS, progression-free survival from osimertinib treatment to PD or death; CI, confidence interval.